JPWO2021237110A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021237110A5 JPWO2021237110A5 JP2022571133A JP2022571133A JPWO2021237110A5 JP WO2021237110 A5 JPWO2021237110 A5 JP WO2021237110A5 JP 2022571133 A JP2022571133 A JP 2022571133A JP 2022571133 A JP2022571133 A JP 2022571133A JP WO2021237110 A5 JPWO2021237110 A5 JP WO2021237110A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- inhibitor
- composition according
- subject
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 50
- 239000003112 inhibitor Substances 0.000 claims 48
- 102000010787 Interleukin-4 Receptors Human genes 0.000 claims 32
- 108010038486 Interleukin-4 Receptors Proteins 0.000 claims 32
- 125000003275 alpha amino acid group Chemical group 0.000 claims 20
- 229940126409 proton pump inhibitor Drugs 0.000 claims 8
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 7
- 208000019505 Deglutition disease Diseases 0.000 claims 6
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 6
- 239000003246 corticosteroid Substances 0.000 claims 6
- 208000012657 Atopic disease Diseases 0.000 claims 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 210000003979 eosinophil Anatomy 0.000 claims 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 102100021935 C-C motif chemokine 26 Human genes 0.000 claims 3
- 108010083698 Chemokine CCL26 Proteins 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 208000004262 Food Hypersensitivity Diseases 0.000 claims 2
- 206010016946 Food allergy Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 102000000743 Interleukin-5 Human genes 0.000 claims 2
- 108010002616 Interleukin-5 Proteins 0.000 claims 2
- 102000000585 Interleukin-9 Human genes 0.000 claims 2
- 108010002335 Interleukin-9 Proteins 0.000 claims 2
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 2
- 239000013566 allergen Substances 0.000 claims 2
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 230000001387 anti-histamine Effects 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 239000000739 antihistaminic agent Substances 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims 2
- 229960001334 corticosteroids Drugs 0.000 claims 2
- 239000000850 decongestant Substances 0.000 claims 2
- 229960003568 dexlansoprazole Drugs 0.000 claims 2
- MJIHNNLFOKEZEW-RUZDIDTESA-N dexlansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-RUZDIDTESA-N 0.000 claims 2
- 235000005911 diet Nutrition 0.000 claims 2
- 230000000378 dietary effect Effects 0.000 claims 2
- 230000010339 dilation Effects 0.000 claims 2
- 229950003468 dupilumab Drugs 0.000 claims 2
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 claims 2
- 229960004770 esomeprazole Drugs 0.000 claims 2
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 claims 2
- 235000020932 food allergy Nutrition 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 239000003862 glucocorticoid Substances 0.000 claims 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims 2
- 230000001861 immunosuppressant effect Effects 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 229960003174 lansoprazole Drugs 0.000 claims 2
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 claims 2
- 238000007726 management method Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229960000381 omeprazole Drugs 0.000 claims 2
- 229940124624 oral corticosteroid Drugs 0.000 claims 2
- 229960005019 pantoprazole Drugs 0.000 claims 2
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 claims 2
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 claims 2
- 239000000612 proton pump inhibitor Substances 0.000 claims 2
- 229960004157 rabeprazole Drugs 0.000 claims 2
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 229940125379 topical corticosteroid Drugs 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 2
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims 2
- 102100023698 C-C motif chemokine 17 Human genes 0.000 claims 1
- 101000978362 Homo sapiens C-C motif chemokine 17 Proteins 0.000 claims 1
- 229940090047 auto-injector Drugs 0.000 claims 1
- 239000000090 biomarker Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000001861 endoscopic biopsy Methods 0.000 claims 1
- -1 esophageal dilation Substances 0.000 claims 1
- 239000011521 glass Substances 0.000 claims 1
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063029085P | 2020-05-22 | 2020-05-22 | |
| US63/029,085 | 2020-05-22 | ||
| US202063066705P | 2020-08-17 | 2020-08-17 | |
| US63/066,705 | 2020-08-17 | ||
| US202063071264P | 2020-08-27 | 2020-08-27 | |
| US63/071,264 | 2020-08-27 | ||
| US202063088147P | 2020-10-06 | 2020-10-06 | |
| US63/088,147 | 2020-10-06 | ||
| US202063121088P | 2020-12-03 | 2020-12-03 | |
| US63/121,088 | 2020-12-03 | ||
| US202163144939P | 2021-02-02 | 2021-02-02 | |
| US63/144,939 | 2021-02-02 | ||
| EP21315068 | 2021-04-21 | ||
| EP21315068.3 | 2021-04-21 | ||
| PCT/US2021/033693 WO2021237110A1 (en) | 2020-05-22 | 2021-05-21 | Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023527775A JP2023527775A (ja) | 2023-06-30 |
| JPWO2021237110A5 true JPWO2021237110A5 (enExample) | 2024-05-28 |
Family
ID=76444669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022571133A Pending JP2023527775A (ja) | 2020-05-22 | 2021-05-21 | Ｉｌ－４ｒ阻害剤の投与により好酸球性食道炎を処置する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250154267A2 (enExample) |
| EP (1) | EP4153300A1 (enExample) |
| JP (1) | JP2023527775A (enExample) |
| KR (1) | KR20230015965A (enExample) |
| CN (1) | CN115768516A (enExample) |
| AU (1) | AU2021277398A1 (enExample) |
| BR (1) | BR112022022235A2 (enExample) |
| CA (1) | CA3174431A1 (enExample) |
| IL (1) | IL298257A (enExample) |
| MX (1) | MX2022014440A (enExample) |
| WO (1) | WO2021237110A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| HUE039387T2 (hu) | 2012-09-07 | 2018-12-28 | Regeneron Pharma | Atópiás dermatitisz kezelési módszerei egy IL-4R antagonista adagolásával |
| TWI755763B (zh) | 2013-06-04 | 2022-02-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
| TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| AU2015222951B2 (en) | 2014-02-28 | 2020-06-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating skin infection by administering an IL-4R antagonist |
| HUE067896T2 (hu) | 2016-04-27 | 2024-11-28 | Abbvie Mfg Management Unlimited Company | Olyan betegségek kezelési módszerei az anti-IL-13 antitestek alkalmazásával, amelyekben az IL-13 aktivitás káros |
| CN109789196B (zh) | 2016-09-01 | 2024-03-19 | 瑞泽恩制药公司 | 用于通过施用il-4r拮抗剂来预防或治疗变态反应的方法 |
| SG11202009371WA (en) | 2018-05-13 | 2020-10-29 | Regeneron Pharma | Methods for treating atopic dermatitis by administering an il-4r inhibitor |
| CN121102493A (zh) | 2019-03-21 | 2025-12-12 | 瑞泽恩制药公司 | 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合 |
| SG11202113312VA (en) | 2019-08-05 | 2021-12-30 | Regeneron Pharma | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist |
| EP4010373A1 (en) | 2019-08-05 | 2022-06-15 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| WO2023212569A1 (en) * | 2022-04-26 | 2023-11-02 | Regeneron Pharmaceuticals, Inc. | Transcriptome analysis for treating inflammation |
| CA3259540A1 (en) * | 2022-07-08 | 2024-01-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating eosinophilic esophagitis in pediatric by administering an il-4r antagonist |
| CN121001741A (zh) | 2023-03-27 | 2025-11-21 | 瑞泽恩制药公司 | 用于通过施用il-4r拮抗剂治疗嗜酸粒细胞性胃肠炎的方法 |
| WO2025221247A1 (en) * | 2024-04-17 | 2025-10-23 | Amgen Inc. | Treatment of eosinophilic esophagitis with anti-tslp antibody |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001092340A2 (en) | 2000-05-26 | 2001-12-06 | Immunex Corporation | Use of interleukin-4 antagonists and compositions thereof |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| CA2543982C (en) | 2003-11-07 | 2013-01-08 | Immunex Corporation | Antibodies that bind interleukin-4 receptor |
| US8030003B2 (en) | 2004-12-07 | 2011-10-04 | Children's Hospital Medical Center | Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3 |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| CA2664343C (en) | 2006-10-02 | 2016-04-26 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human il-4 receptor |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| SG189220A1 (en) | 2010-10-06 | 2013-05-31 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
| HRP20180421T1 (hr) * | 2010-11-17 | 2018-04-20 | Chugai Seiyaku Kabushiki Kaisha | Višestruko specifične molekule za vezanje na antigen koje imaju alternativnu funkciju u odnosu na funkciju faktora viii zgrušavanja krvi |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| TWI634900B (zh) * | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| HUE067896T2 (hu) * | 2016-04-27 | 2024-11-28 | Abbvie Mfg Management Unlimited Company | Olyan betegségek kezelési módszerei az anti-IL-13 antitestek alkalmazásával, amelyekben az IL-13 aktivitás káros |
| CN107474134B (zh) | 2016-06-08 | 2021-07-27 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
| TWI728172B (zh) * | 2016-08-18 | 2021-05-21 | 美商愛戴爾製藥股份有限公司 | 治療嗜伊紅性食道炎之方法 |
| WO2019028367A1 (en) | 2017-08-04 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES |
| IL315556A (en) * | 2017-08-04 | 2024-11-01 | Regeneron Pharma | Methods for treating active eosinophilic esophagitis |
| EP3755432A4 (en) * | 2018-02-21 | 2021-12-01 | Ellodi Pharmaceuticals, L.P. | METHOD OF TREATMENT OF EOSINOPHILIC ESOPHAGITIS |
| CA3103151A1 (en) * | 2018-06-14 | 2019-12-19 | Ajinomoto Co., Inc. | Compound having affinity substance to antibody and bioorthogonal functional group, or salt thereof |
| CN113166259A (zh) | 2018-11-09 | 2021-07-23 | 亚洲大学校产学协力团 | 对人IL-4受体α具有高亲和力的人抗体及其用途 |
-
2021
- 2021-05-21 JP JP2022571133A patent/JP2023527775A/ja active Pending
- 2021-05-21 WO PCT/US2021/033693 patent/WO2021237110A1/en not_active Ceased
- 2021-05-21 KR KR1020227045054A patent/KR20230015965A/ko active Pending
- 2021-05-21 AU AU2021277398A patent/AU2021277398A1/en active Pending
- 2021-05-21 BR BR112022022235A patent/BR112022022235A2/pt unknown
- 2021-05-21 EP EP21732754.3A patent/EP4153300A1/en active Pending
- 2021-05-21 CN CN202180036330.4A patent/CN115768516A/zh active Pending
- 2021-05-21 CA CA3174431A patent/CA3174431A1/en active Pending
- 2021-05-21 MX MX2022014440A patent/MX2022014440A/es unknown
- 2021-05-21 US US17/327,504 patent/US20250154267A2/en active Pending
- 2021-05-21 IL IL298257A patent/IL298257A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021237110A5 (enExample) | ||
| JP6306588B2 (ja) | Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法 | |
| CN105517570B (zh) | 通过施用il-4r拮抗剂治疗鼻息肉症的方法 | |
| JP2016523863A5 (enExample) | ||
| CN115768516A (zh) | 通过施用il-4r抑制剂治疗嗜酸细胞性食管炎的方法 | |
| JP2022160685A5 (enExample) | ||
| JP2020500152A5 (enExample) | ||
| US20200206227A1 (en) | Tyrosine kinase inhibitor formulations for the treatment of mast cell-mediated inflammatory diseases and methods of use thereof | |
| IL316404A (en) | A safe and effective method for treating psoriasis with a specific anti-IL23 antibody | |
| JP2020502261A5 (enExample) | ||
| Stokes et al. | Rationale for new treatments aimed at IgE immunomodulation | |
| JPWO2019222055A5 (enExample) | ||
| JP2025072440A5 (enExample) | ||
| JP2024016237A5 (enExample) | ||
| JPWO2017172771A5 (enExample) | ||
| JPWO2021026205A5 (enExample) | ||
| CN1612751A (zh) | 包括施用抗IgE抗体和抗过敏化合物、用于过敏性疾病的组合治疗 | |
| JP6898421B2 (ja) | Ｉｌ−４ｒアンタゴニストの投与により鼻茸を処置する方法 | |
| JP2020073525A5 (enExample) | ||
| JPWO2021195530A5 (enExample) | ||
| CN115942933A (zh) | 用于治疗气道疾病的(1r,3s)-3-((5-氰基-4-苯基噻唑-2-基)氨基甲酰基)环戊烷-1-羧酸及其衍生物 | |
| JP2005526022A5 (ja) | 関節リウマチの処置 | |
| JP2020529434A5 (enExample) | ||
| CN119546337A (zh) | 通过施用il-4r拮抗剂治疗小儿嗜酸性粒细胞性食管炎的方法 | |
| Colice | Emerging therapeutic options for asthma |